Since the beginning of 2022, there has been an increase in the incidence of anaphylactic-type reactions in cattle after administration of HIPRABOVIS IBR MARKER LIVE vaccine. The cause has not yet been clearly identified and investigations are ongoing. Veterinarians are asked to report any adverse reactions as soon as possible and, if possible, to provide a complete history of vaccinations and an overview of other veterinary medicinal products previously used.
From March 2022 to May 2022, a total of 27 cases involving 175 animals with an anaphylactic-like reaction and 8 dead animals were observed. At least 5 of the animals that died had anaphylactic-type reactions with fatal outcomes. The majority of these cases were reported in specific geographic areas of Spain (19/27) and Italy (7/27). This situation has not been observed in other European Union (EU) countries where the vaccine is currently used. In most cases, several other vaccines had been administered to the animals previously and/or concomitantly. During this period, more than 641 075 doses were administered in 14 EU countries.
The cause of these cases has not yet been clearly identified and investigations are ongoing. Product information will be updated based on the frequency and severity of hypersensitivity/anaphylactic reactions.
Report adverse reactions
It is important to report adverse reactions promptly after administration of HIPRABOVIS IBR MARKER LIVE vaccine. This allows for continuous monitoring of the safety of a veterinary medicinal product. Direct communication with animal health professionals (DaHPC) was sent. Veterinarians can report any suspected adverse reaction via the national reporting system for veterinary medicinal products. The full vaccination history and an overview of other veterinary medicinal products previously used in reacting animals, where possible, including the name(s) of the product(s) and batch details, should also be provided in the reports, if available.